Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Primary Target

Solute carrier family 12 member 1

2

Histamine H1 receptor

315

Dopamine D2 receptor

297

DNA

278

Bacterial penicillin-binding protein

233

All Match

Any Match

Exclude Selected

Exclude Selected

Development Status

US Approved Rx

2

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

2

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1983

2

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Edema

2

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

2

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Active

2

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Leo Pharma

2

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

2

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

2

ECHA (EC/EINECS)

2

EPA CompTox

2

FDA UNII

2

PUBCHEM

2

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

CARDIOVASCULAR SYSTEM

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

DIURETICS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION

1

HIGH-CEILING DIURETICS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

High-ceiling diuretics and potassium-sparing agents

1

Sulfonamides and potassium in combination

1

Sulfonamides, plain

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Principal Form

1

Salts, Hydrates, Esters, etc.

1

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 2 of 2 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

BUMETANIDE

0Y2S3XUQ5H

Export Data
Search for Structure

Status:

US Approved Rx (2008)

First approved in 1983

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Solute carrier family 12 member 4

Solute carrier family 12 member 2

Solute carrier family 12 member 1

Solute carrier family 12 member 5

Conditions:

Bumetanide is indicated for the treatment of edema associated with congestive heart failure, hepatic and renal disease, including the nephrotic syndrome. It blocks the reabsorption of sodium and fluid from the kidney's tubules. The most frequent clin...

ical adverse reactions considered probably or possibly related to bumetanide are muscle cramps (seen in 1.1% of treated patients), dizziness (1.1%), hypotension (0.8%), headache (0.6%), nausea (0.6%) and encephalopathy (in patients with preexisting liver disease) (0.6%). One or more of these adverse reactions have been reported in approximately 4.1% of patients treated with Bumex (bumetanide). Lithium should generally not be given with diuretics (such as Bumex (bumetanide)) because they reduce its renal clearance and add a high risk of lithium toxicity. Bumex (bumetanide) may potentiate the effect of various antihypertensive drugs, necessitating a reduction in the dosage of these drugs.

BUMETANIDE SODIUM

1QC8KM52D1

Export Data
Search for Structure

Status:

US Approved Rx (2008)

First approved in 1983

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Solute carrier family 12 member 4

Solute carrier family 12 member 2

Solute carrier family 12 member 1

Solute carrier family 12 member 5

Conditions:

Bumetanide is indicated for the treatment of edema associated with congestive heart failure, hepatic and renal disease, including the nephrotic syndrome. It blocks the reabsorption of sodium and fluid from the kidney's tubules. The most frequent clin...

ical adverse reactions considered probably or possibly related to bumetanide are muscle cramps (seen in 1.1% of treated patients), dizziness (1.1%), hypotension (0.8%), headache (0.6%), nausea (0.6%) and encephalopathy (in patients with preexisting liver disease) (0.6%). One or more of these adverse reactions have been reported in approximately 4.1% of patients treated with Bumex (bumetanide). Lithium should generally not be given with diuretics (such as Bumex (bumetanide)) because they reduce its renal clearance and add a high risk of lithium toxicity. Bumex (bumetanide) may potentiate the effect of various antihypertensive drugs, necessitating a reduction in the dosage of these drugs.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1